Pub. Date : 2016 Nov
PMID : 27859541
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | RESULTS: Ambroxol treatment resulted in increased brain glucocerebrosidase activity in (1) wild-type mice, (2) transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and (3) transgenic mice overexpressing human alpha-synuclein. | Ambroxol | synuclein alpha | Homo sapiens |
| 2 | Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels. | Ambroxol | synuclein alpha | Homo sapiens |
| 3 | Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels. | Ambroxol | synuclein alpha | Homo sapiens |
| 4 | Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels. | Ambroxol | synuclein alpha | Homo sapiens |
| 5 | INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease alpha-synuclein and phosphorylated alpha-synuclein protein levels. | Ambroxol | synuclein alpha | Homo sapiens |
| 6 | INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease alpha-synuclein and phosphorylated alpha-synuclein protein levels. | Ambroxol | synuclein alpha | Homo sapiens |